US 11,084,865 B2
VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
Log In
Please sign up or log in to access the advanced features of
Ex Parte Enterprise.
or Log in

General

US 11,084,865 B2
VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Christine J Saoud
Art Unit:
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Agent:
Bozicevic Field & Francis LLP
Inventors:
Eric FURFINE; Daniel DIX; Kenneth GRAHAM; Kelly FRYE
Assignee:
REGENERON PHARMACEUTICALS, INC.
Priority:
06/14/07
Filed:
01/10/20
Granted:
08/10/21
Expiration:
06/16/26
Abstract
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Cooperative Patent Classification (CPC)
A61A61K38/1793A61P43/00A61M5/178A61KC07K14/4705C07K

Analytics

Cases

Patent Assignments

Citations